D-dimer, a degradation product of cross-linked fibrin formed during activation of the coagulation system, is commonly used to exclude thromboembolic disease in outpatients suspected of having deep venous thrombosis (DVT) and pulmonaryembolism (PE).[1] DVT and PE is relatively common and can cause sudden, fatal embolic events in the pulmonary arteries and other regions. [2-3] Measurement of the D-Dimer level in plasma has been used as a screening strategy for subclinical DVT. A systematic review reported that a normal range of a highly sensitive D-dimer level accurately ruled out DVT in patients classified as having a low or moderate clinical probability of DVT. The DVT is a high-risk factor for the stroke because of advanced age, hemiplegia, and coagulation disorders, and DVT can cause paradoxical embolic stroke via a right-to left shunt. Thus, it is important to monitor the level of D-Dimer the incidence and characteristics of DVT in acute stroke patients.[4-7] The Plasma D-dimer level has proven to be useful for DVT screening in chronic stroke patients undergoing rehabilitation.[8-10] National and international scientific organizations have suggested the use of these markers when implementing new diagnostic strategies in patients with coronary syndrome. Since D-Dimer is well known to be an important prognostic indicator of heart diseases, its most definitive role is on monitoring post-treatment clinical status and the post therapeutic evaluation of Patients

References

• 1. Performance of two relatively new quantitative D-dimer assays (Innovance D-dimer and AxSYM D-dimer) for the exclusion of deep vein thrombosis J.L. Elf K. Strandberg b, P.J. Svensson b J.L. Elf et al. / Thrombosis Research 124 (2009) 701–705
• 2. Rowbotham BJ, Caroll P, Whitaker AN, Bunce IH, Cobcroft RG, Elms MJ, et al.Measurement of crosslinked fibrin derivates- use in the diagnosis of venous thrombosis. Thromb Haemost 1987;57:59–61.
• 3. Stein PD, Hull RD. D-dimer for the exclusion of acute deep vein thrombosis and pulmonary embolism: A systematic review. Ann Intern Med 2004;140(8):589–602. [4] Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350:1795–8.
• 4. Comparison of an immuno-turbidometric method (STalia_R D-DI) with an established enzyme linked fluorescent assay (VIDAS_R ) D-dimer for the exclusion of venous thromboembolism Journal compilation _ 2007 Blackwell Publishing Ltd, Int. Jnl. Lab. Hem. 2008, 30, 200–204
• 5. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a posthoc analysis of the PROLONG study haematologica | 2008; 93(6) | 901
• 6. Performance characteristics of the AxSYM D-dimer assay Sonia L. La'ulu a, Camille M. Dominguez b, William L. Roberts c, S.L. La'ulu et al. / Clinica Chimica Acta 390 (2008) 148–151
• 7. Analytical performances of the D-dimer assay for the Immulite 2000 automated immunoassay analyser G. LIPPI*, G. L.SALVAGNO*, L. ROSSI*, M. MONTAGNANA*, M. FRANCHINI†, G. C. GUIDI Journal compilation _ 2007 Blackwell Publishing Ltd, Int. Jnl. Lab. Hem. 2007, 29, 415–420
• 8. Diagnostic accuracy of the Triage® D-dimer test for exclusion of venous thromboembolism in outpatients Timothy Ghys , Wim Achtergael, Inge Verschraegen, Jochmans Thrombosis Research (2008) 121, 735–741
• 9. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005;365:1163–74.
• 10. VIDAS#{174}D-dimer: fast quantitative ELISA for measuring Ddimer in plasma JEAN-LOUIS PITTET,l* PHILIPPE DE MOERLOOSE,5 GuIDo REBER,5 CATHERINE DURAND,1 CECILE VILLARD,2 NADIA PIGA,2 DOMINIQUE ROLLAND,3 SERGE COMBY,4 and GEORGES Dupuy1 Clinical Chemistry 42, No. 3,1996.

ichroma™

AFIAS

Product News